Evidence map›Paper›PMID 37268673›Full record

ArticleScientific reports2023

Increased plasma lipids in triple-negative breast cancer and impairment in HDL functionality in advanced stages of tumors.

Maria Isabela Bloise Alves Caldas Sawada, Monique de Fátima Mello Santana, Mozania Reis, Sayonara Ivana Santos de Assis, Lucas Alves Pereira, Danielle Ribeiro Santos, Valéria Sutti Nunes, Maria Lucia Cardillo Correa-Giannella, Luiz Henrique Gebrim, Marisa Passarelli

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Frontiers in immunology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Maria Isabela Bloise Alves Caldas SawadaPrograma de Pós-Graduação em Medicina, Universidade Nove de Julho (UNINOVE), São Paulo, Brazil.
Monique de Fátima Mello SantanaLaboratório de Lípides (LIM10), Hospital das Clínicas (HCFMUSP) da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Mozania ReisPrograma de Pós-Graduação em Medicina, Universidade Nove de Julho (UNINOVE), São Paulo, Brazil.
Sayonara Ivana Santos de AssisLaboratório de Lípides (LIM10), Hospital das Clínicas (HCFMUSP) da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Lucas Alves PereiraPrograma de Pós-Graduação em Medicina, Universidade Nove de Julho (UNINOVE), São Paulo, Brazil.
Danielle Ribeiro SantosLaboratório de Lípides (LIM10), Hospital das Clínicas (HCFMUSP) da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Valéria Sutti NunesLaboratório de Lípides (LIM10), Hospital das Clínicas (HCFMUSP) da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Maria Lucia Cardillo Correa-GiannellaLaboratório de Carboidratos e Radioimunoensaio Lípides (LIM18), Hospital das Clínicas (HCFMUSP) da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Luiz Henrique GebrimCentro de Referência da Saúde da Mulher (Hospital Pérola Byington), São Paulo, Brazil.
Marisa PassarelliPrograma de Pós-Graduação em Medicina, Universidade Nove de Julho (UNINOVE), São Paulo, Brazil. m.passarelli@uni9.pro.br.
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRUniversidade Nove de Julho · BRHospital da Mulher São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The association between plasma lipids and breast cancer (BC) has been extensively explored although results are still conflicting especially regarding the relationship with high-density lipoprotein cholesterol (HDLc) levels. HDL mediates cholesterol and oxysterol removal from cells limiting sterols necessary for tumor growth, inflammation, and metastasis and this may not be reflected by measuring HDLc. We addressed recently diagnosed, treatment-naïve BC women (n = 163), classified according to molecular types of tumors and clinical stages of the disease, in comparison to control women (CTR; n = 150) regarding plasma lipids and lipoproteins, HDL functionality and composition in lipids, oxysterols, and apo A-I. HDL was isolated by plasma discontinuous density gradient ultracentrifugation. Lipids (total cholesterol, TC; triglycerides, TG; and phospholipids, PL) were determined by enzymatic assays, apo A-I by immunoturbidimetry, and oxysterols (27, 25, and 24-hydroxycholesterol), by gas chromatography coupled with mass spectrometry. HDL-mediated cell cholesterol removal was determined in macrophages previously overloaded with cholesterol and

Indexed as

OxysterolsTriple Negative Breast NeoplasmsApolipoprotein A-ICholesterolCholesterol, HDLFemaleGas Chromatography-Mass SpectrometryHumansLipoproteinsTriglyceridesApolipoprotein A-ICholesterolCholesterol, HDLLipoproteinsOxysterolsTriglycerides

Identifiers

PMID37268673
PMCPMC10238519
OpenAlexW4379197498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.